Tag: ilmn

Don’t spend $450 on a pair of sneakers. Here are 10 stocks you could buy instead.

Don’t spend $450 on a pair of sneakers. Here are 10 stocks you could buy instead.

ericmilton

As some of you may know, I currently have a day job.

My job is to help displaced individuals find employment. I don’t help them find their dream job…my purpose is to help them find a job.

Yesterday, I met two young adults, back to back, each wearing a pair of sneakers called  Yeezys.

In case you don’t know, Yeezys are sneakers made and marketed by Kanye West. They retail for $250 – for the lucky few that can find them. The demand for these sneakers is so high that you will most likely have to pay a lot more than $250 for them.

On the secondary market, these sneakers are flipped to people like the two candidates I saw today for $450 a pair. When I learned this, I almost fell out of my chair!

To make matters worse, these are individuals at the lower end of the pay scale. My interaction with these individuals inspired me to write this post.

If you are planning on buying a pair of $450 sneakers, let me give you ten stock ideas to buy instead that can pay off big time in five to ten years…

1. Illumina (NASDAQ: ILMN): the gene sequencing giant.

2. Roku (NASDAQ: ROKU): the over the top (OTT) operating system for streaming video.

3. Apple (NASDAQ: APPL): the most valuable company in the world.

4. Tesla (NASDAQ: TSLA): the pioneer of the electric car movement.

5. Nvidia (NASDAQ: NVDA): the leader in artificial intelligence (AI). Has its hand in every major technology platform in the future.

6. The Trade Desk (NASDAQ: TTD): a pioneer in digital advertising.

7. NIKE (NYSE: NKE): one of the most recognized brands in the world.

8. Lululemon (NASDAQ: LULU): maybe the most innovative company in apparel.

9. MasterCard (NYSE: MA): one of the dominant players in digital payments.

10. Facebook (NASDAQ: FB): whether you love Facebook or hate it, it and Google have a duopoly on digital marketing – and that dominance is not going away any time soon.

 

My book, The Stock Market is For Everyone, is a short guide for the beginning, inexperienced investor that is easy to understand and can be put into action immediately.

Click the image of the book at left to be taken to its Amazon page.  (Disclosure: As a participant in the Amazon Services LLC Associates Program, I earn a small commission on each sale generated through these links.)

 

 

 

 

 

 

 

3 Stocks For The Genomics Revolution

3 Stocks For The Genomics Revolution

ericmilton

Over the next five years, the projection is that genomics is going to explode.

Genomics is the study of our DNA.

The cost of having your genome sequenced has dropped from billions to thousands of dollars – and will probably be as low as $100 in the near future.

This is significant. For one thing, the reduced cost has led to insurance companies starting to pay for patients to have clinical grade DNA tests, in the hopes of catching disease in its earliest stages.

Over the next five years, ARK Invest believes that the number of genomes sequenced will rise from 1.5 million tested in 2018 to 100 million by 2023.

If that is the case, it should be very positive for companies that specialize in genomics.

Here are three companies you may want to look into:

  1. Illumina (NASDAQ: ILMN): Illumina is the most dominant company in the genomics field, because 90% of all genes sequenced in the world are done so by using their machines. They are single-handedly responsible for driving down the cost of sequencing a whole human genome from millions of dollars to under a thousand and on the road to ultimately below $100.
  2. Invitae (NYSE: NVTA): Invitae is a much smaller company. But it has its sights on becoming the “Amazon of genomics” by making it very easy and convenient for people to get comprehensive genetic testing done during their yearly doctor’s visit.
  3. Veracyte (NASDAQ: VCYT): Another up and coming small-cap company in genomics. Veracyte is a genomics diagnostic company. The company is transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.

Over the next five years, genomes sequenced are projected to grow 85% annually.

I don’t know if that will come to fruition, but if it does…that’s incredible growth!

 

My book, The Stock Market is For Everyone, is a short guide for the beginning, inexperienced investor that is easy to understand and can be put into action immediately.

Click the image of the book at left to be taken to its Amazon page.  (Disclosure: As a participant in the Amazon Services LLC Associates Program, I earn a small commission on each sale generated through these links.)